Daunorubicin induced Stevens‐Johnson syndrome: A case report
Authors:
Open Access
- 16 July 2021
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 9 (7) , e04475
Abstract
Clinicians should consider the possible association of Daunorubicin with Stevens‐Johnson syndrome (SJS), administer it with caution and promptly evaluate all subsequently developing cutaneous reactions with a high index of suspicion for Stevens‐Johnson syndrome.Keywords
All Related Versions
This publication has 6 references indexed in Scilit:
- Life-threatening dermatologic adverse events in oncologyAnti-Cancer Drugs, 2014
- Stevens-johnson syndrome: a case report.2009
- Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-StudyJournal of Investigative Dermatology, 2008
- Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and IsraelJournal of the American Academy of Dermatology, 2008
- Comparison of Reporting of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Selective COX-2 InhibitorsDrug Safety, 2005
- Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal NecrolysisNew England Journal of Medicine, 1995